Akebia Therapeutics (AKBA) traded up 0.89 % during a 24 hours period ending at 04:42 PM Central Europe on Monday 26th. One Akebia Therapeutics stock can currently be bought for about USD 0.66 on popular exchanges. Current supply of Akebia Therapeutics stocks is 277.1 mn. Akebia Therapeutics has a current market capitalization of USD 157.1 mn and approximately USD 6.2 mn worth of Akebia Therapeutics was traded on exchanges in the last 24 hours. Since last month end, Akebia Therapeutics has traded -38.3 % down. Simple moving average of last 200 days is at USD 1.16. The highest price of past 52 weeks was recorded at USD 3.2 on 10/28/2025. 52 weeks low was at USD 0.54 on 10/22/2026.
Here is how related stocks have performed in the past 24 hours:
Bayfirst (BAFN) traded up 0.44 % and now trades at USD 6.71. Bayfirst has a market capitalisation of USD 185.5 mn.
Evommune (EVMN) traded down -2.11 % and now trades at USD 5.23. Current market capitalisation for Evommune is USD 185.1 mn.
Inogen (INGN) traded up 0.85 % and now trades at USD 7.03. Current market capitalisation for Inogen is USD 188.4 mn.
Eledon (ELDN) traded flat 0 % and now trades at USD 2.23. Current market capitalisation for Eledon is USD 187.1 mn.
Cartesian Therapeutics (RNAC) traded down -3.59 % and now trades at USD 6.21. Current market capitalisation for Cartesian Therapeutics is USD 187 mn.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, USA, that specializes in manufacturing biopharmaceutical products. The company has its sights set on developing and distributing novel therapeutics based on hypoxia inducible factor (HIF) for patients with kidney diseases. Akebia Therapeutics serves its customers in the United States and can be accessed through its website at www.akebia.com . The company went public on the Nasdaq stock exchange on March 20, 2014.
